In lobular BC, the loss of E-cadherin expression that occurs early in the tumorigenic process [46], could be rescue by ROS1 synthetic lethality, an effect clinically actionable using ROS1 inhibitors [47]. This evidence concerns the gene CDH1 and breast cancer.